Dragonfly Sciences, Inc. Information

Dragonfly Sciences is a leader in developing a new class of biosimilar products of complex monoclonal antibodies and soluble receptors. The company’s technology platform integrates advanced biology tools and precision bioanalytics necessary to develop products to meet the most rigorous regulatory standards for safety and efficacy. Therapeutic monoclonal antibodies are one of the most important contributions of the biotechnology industry. Since monoclonal antibodies were introduced for use, they have established themselves as blockbuster drugs for treating serious and life threatening disorders ranging from cancer to autoimmune diseases. While these drugs represent genuine breakthroughs, they remain expensive therapies. Dragonfly is committed to developing and marketing the highest quality biosimilar products while lowering their cost and improving patient access. Dragonfly is led by a management team with extensive experience in the successful discovery and development of therapeutic proteins and antibodies dedicated to applying that experience to the emerging area of biosimilar products.